Approval · Notice of Compliance 33875 · 2024
MS CONTIN: Notice of Compliance 33875
Issued August 27, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33875
- Date
- August 27, 2024
- Company
- Purdue PharmaToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph with new safety information. Update to Patient Medication Information. Update to package insert
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MS CONTIN | Not yet assigned | — |
Medicinal ingredients
- MORPHINE SULFATE 15 MG per TAB
- MORPHINE SULFATE 30 MG per TAB
- MORPHINE SULFATE 60 MG per TAB
- MORPHINE SULFATE 100 MG per TAB
- MORPHINE SULFATE 200 MG per TAB